Amgen Inc. (AMGN) announced that its Phase 3 OASIZ 301 trial evaluating the treatment of Sjogren's disease with the drug candidate dazodalibep has met its primary endpoint. The trial demonstrated improvement in systemic disease activity at Week 48.
The OASIZ 301 trial is a pivotal study designed to assess the efficacy of dazodalibep in patients with Sjogren's disease. The primary endpoint of the study was the improvement in systemic disease activity at Week 48.
Amgen stated that the results of the OASIZ 301 trial show that the treatment met its primary endpoint. The company noted that the data indicates improvement in systemic disease activity at the 48-week mark.
